BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Consort Medical to Sell King Division for $170 Million


12/27/2012 8:39:17 AM

Medical devices maker Consort Medical Plc (CSRT.L) Thursday announced the proposed sale of its King Systems Corp., division to Danish diagnostic and life-supporting equipment developer Ambu A/S for a maximum consideration of $170 million or 105 million pounds. Following the disposal, Consort will be a focused pharmaceutical services business. The shares rose about 6 percent in the morning trade. Consort stated that the consideration consists of an initial payment of $120 million and further contingent payments of up to $50 million, receivable over the next three years. Consort and Ambu have signed a sale and purchase agreement, under which Ambu will acquire the entire issued capital stock of King. The disposal is expected to be completed in the first quarter of calendar 2013. Founded in 1977, Consort's King division manufactures and markets disposable airway management products and receives about 87 percent of its revenue from the US markets. As at October 31, 2012, the business had gross assets of 85.9 million pounds. For the year ended April 30, 2012, it generated a loss before tax and after special items of 0.8 million pounds. The company said its strategy is to focus increasingly on pharmaceutical services and drug delivery opportunities that complement its core Bespak business division. Consort intends to retain the proceeds to strengthen its balance sheet. Jonathan Glenn, chief executive of Consort stated, "With our strengthened balance sheet, we will be able to consider investments to re-allocate our capital into growth opportunities that complement Bespak, but only within strict financial criteria."

Read at RTT News
Read at Market Watch
Read at Reuters
Read at Financial Times

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES